Status:

RECRUITING

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Chronic Kidney Failure

End-Stage Renal Disease

Eligibility:

All Genders

24-85 years

Phase:

PHASE1

Brief Summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain type...

Eligibility Criteria

The main inclusion criteria include but are not limited to the following:

  • Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.

Severe Renal Impairment Participants:

  • Has an estimated glomerular filtration rate (eGFR) < 30 mL/min), but is not on hemodialysis (HD)

ESRD on HD Participants:

  • Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for > 3 months prior to study entry

The main exclusion criteria include but are not limited to the following:

Renal Impairment Participants:

  • History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.

Healthy Matched Control Participants:

  • History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.

Key Trial Info

Start Date :

March 2 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 18 2026

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT07348237

Start Date

March 2 2026

End Date

August 18 2026

Last Update

April 2 2026

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Panax Clinical Research ( Site 0003)

Miami Lakes, Florida, United States, 33014

2

Floridian Clinical Research ( Site 0001)

Miami Lakes, Florida, United States, 33016

3

Orlando Clinical Research Center ( Site 0002)

Orlando, Florida, United States, 32809